A
AEON
AEON Biopharma, Inc.
$0.23
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of AEON Biopharma, Inc. in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$3.58
P/E
—
Data as of Oct 8
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Posts
No posts about AEON yet.
About AEON Biopharma, Inc.
AEON Biopharma is a small clinical-stage drug company, which means it is still testing its medicines and has no approved product to sell. Its main program is a purified botulinum toxin (the same family of drug as Botox) being developed for conditions such as migraine and movement disorders. The company earns no product revenue today. It pays its bills by raising money from investors, and it hopes to earn revenue later if regulators approve a drug.